BCG vaccine nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG. The global supply situation was analyzed in 2017 and concluded that the global supply is sufficient to meet forecasted BCG vaccine demand but risks for shortages remain mainly due to supply concentration. A weakened strain of bovine tuberculosis bacillus, "Mycobacterium bovis" is specially subcultured in a culture medium, usually Middlebrook 7H9. Some BCG vaccines are freeze dried and become
Inoculation theory body to a weakened form of a virus—strong enough to trigger a response (i.e., the production of antibodies), but not so strong as to overwhelm the body's resistance. Attitudinal inoculation works the same way: Expose the receiver to weakened counterarguments, triggering a process of counterargument which confers resistance to later, stronger persuasive messages. This process works like a metaphorical vaccination: the receiver becomes immune to attacking messages that attempt to change their attitudes or beliefs regarding the initial threat. Inoculation theory suggests that if one sends out messages with weak counterarguments, an individual can build immunity to those messages and